EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review

Nawaf Almuntashiri, Basma M El Sharazly iD, Wayne G Carter iD

Biomolecules · 04.06.2025 · 15 (6) · 816

DOI: 10.3390/biom15060816 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Biomolecules, online erschienen am 04.06.2025. Verfasst von Nawaf Almuntashiri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Toxicology Research Group, School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby DE22 3DT, UK. Hauptthemen laut MEDLINE: Cannabinoids, Cannabis, Medical Marijuana, Neuralgia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cultural Bureau and Ministry of Education Saudi Arabia, Cultural Bureau and Ministry of Education PhD Scholarship, Kingdom of Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuropathic pain is a chronic disorder that arises from damaged or malfunctioning nerves. Hypersensitivity to stimuli, also known as hyperalgesia, can cause a person to experience pain from non-painful stimuli, termed allodynia. Cannabis-based medicines (CBMs) may provide new treatment options to manage neuropathic pain. A review of the relevant studies was conducted to evaluate the effectiveness of CBMs in treating neuropathic pain. Scientific literature was systematically searched from January 2003 to December 2024 using the Web of Science Core Collection, PubMed, and MEDLINE. A total of 22 randomized controlled trials (RCTs) were identified that considered the use of 1′,1′-dimethylheptyl-Δ8-tetrahydrocannabinol-11-oic acid (CT-3), Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), combinations of Δ9-THC with CBD, and cannabidivarin for treatment of neuropathic pain. Significant reductions in pain were reported in 15 studies focused on the treatment of multiple sclerosis, spinal cord injuries, diabetic neuropathy, postherpetic neuralgia, HIV-associated sensory neuropathy, peripheral neuropathic pain, complex regional pain syndrome, chronic radicular neuropathic pain, and peripheral neuropathy of the lower extremities. These positive outcomes often adopted personalized and adjusted dosing strategies. By contrast, seven RCTs observed no significant pain relief compared to placebo, although some had minor improvements in secondary outcomes, such as mood and sleep. Collectively, CBM treatments may improve pain scores, but study limitations such as small sample sizes and study durations, high placebo response rates, and trial unblinding because of the psychoactive effects of cannabinoids all hinder data interpretation and the extrapolation to chronic pain conditions. Hence, future RCTs will need to have larger numbers and be more extended studies that explore optimal dosing and delivery methods and identify patient subgroups that are most likely to benefit. While CBMs show potential, their current use balances modest benefits against possible adverse effects and variable outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsCannabisMedical MarijuanaNeuralgiaHumansCannabidiolDronabinolRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

cannabidiolcannabidivarincannabis-based medicinesneuropathic painΔ9-tetrahydrocannabinol (THC)

Substanzen

CannabidiolCannabinoidsDronabinolMedical Marijuana

Autor:innen und Institutionen

  • Clinical Toxicology Research Group, School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby DE22 3DT, UK.
  • Forensic Toxicology Services Administration, Ministry of Health, P.O. Box 290, Makkah 25315, Saudi Arabia.
  • Parasitology Department, Faculty of Medicine, Tanta University, Tanta 31111, Gharbia Governorate, Egypt.

ORCID-Profile: Basma M El Sharazly, Wayne G Carter

Förderung

  • Cultural Bureau and Ministry of Education Saudi Arabia
  • Cultural Bureau and Ministry of Education PhD Scholarship, Kingdom of Saudi Arabia

Zitieren

APA

Almuntashiri, N., El Sharazly, B. M., & Carter, W. G. (2025). Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review. Biomolecules, 15(6), 816. https://doi.org/10.3390/biom15060816

Vancouver

Almuntashiri N, El Sharazly BM, Carter WG. Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review. Biomolecules. 2025;15(6):816. doi:10.3390/biom15060816

BibTeX
@article{Almuntashiri2025,
  author = {Almuntashiri, Nawaf and El Sharazly, Basma M and Carter, Wayne G},
  title = {Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {816},
  doi = {10.3390/biom15060816}
}
Kostenlos starten →